Missouri lawmakers recently approved a Republican-led bill to expand research on the therapeutic benefits of certain psychedelics including psilocybin, MDMA, and ketamine. If passed, the bill would legalize psychedelic-assisted therapy for certain patients, while expanding legal protections and promoting research efforts under the state’s existing “right to try” law for people with serious chronic conditions.
House Bill 1154
HB 1154 was introduced by Representative Dan Houx (R) back in February of this year. It has moved through several committees and now the full chamber has granted initial approval to an amended version, which is expected to pass and move to the Senate for a vote sometime next week. Houx mentioned that he’s very pleased with the turnout so far, stating on the floor prior to the vote that “psilocybin is a natural substance that is helping our veterans throughout the state and throughout the country—actually around the world.”
Chairman Dave Griffith (R), who has been involved with the bill since early on, that he’s not only excited, but also very surprised how drastically the discussion around psychedelics has shifted over the years. “If you had told me five years ago that I would be chairing a committee and considering a bill about psychedelics for veterans, I would have thought you were crazy,” he said. “This speaks volumes that such ‘out-there’ discussions can now even approach reality and trigger meaningful change.”
Initially, the proposal focused on semi-equal expansion of three different hallucinogens – psilocybin, MDMA, and ketamine – but new revisions, at the request of some of the bill’s sponsors, tightened the parameters around the latter two substances while broadening provisions for people who use, possess, cultivate, distribute, and administer psilocybin products.
The legislation would allow Missouri’s Department of Health and Human Services to work with the U.S. Department of Veterans Affairs (VA) to conduct studies on how hallucinogenic drugs can be used to help mediate certain mental health disorders such as post-traumatic stress disorder, drug and alcohol addiction, and severe depression, as well conditions related to end-of-life care.
So far, the plan will be that patients can receive psilocybin treatments for a maximum of one-year, with the treatment capped at 150 milligrams. There will be options for qualifying patients to continue treatments in ongoing, one-year intervals.
Additionally, there will be some more legal protections laid out to protect industry participants from local or state prosecution. These protections will extend to patients, prescribers, regulators, and state agency officials who are conducting lawful activity under the new regulations.
House Bill 869
Downtown St. Louis, Missouri
Also discussed, but not yet advanced, was HB 869 – a bill introduced by Representative Tony Lovasco (R). The goal of this proposal was to “provide those who use psilocybin to treat certain conditions an affirmative defense against prosecution”; although members of the committee ultimately decided not to work this one in.
The bill states that, “The medical use of natural medicine by eligible patients and their caregivers is allowed under state and local law in accordance with this section. Notwithstanding any other provision of law, the medical use of natural medicine by an eligible patient or caregiver in compliance with this section is not subject to criminal or civil liability under the laws of this state.”
While HB 869 would not legalize magic mushrooms, it would allow people to possess up to 4 grams of psilocybin and provide an added layer of protection to doctors who prescribe products containing it. Furthermore, the DHSS would oversee the whole operation to guarantee that products are safe and effective. Houx stated that although he believed Lovasco’s measure went “too far”, he still plans to collaborate with him to draft an amendment they can both agree on.
Final thoughts
The way Missouri has been rocking their adult-use cannabis market, it’s no surprise they’re on the right path with psychedelics as well. So far this year, we have seen incredible progress on this front nationwide, with over a dozen states having proposed new laws to decriminalize and expand research programs on hallucinogens. But what’s interesting about this bill in Missouri is that it’s led and sponsored by Republicans, who are known to generally be more conservative in regard to these issues. But it shows that psychedelic reform, and especially, psychedelic-assisted therapy, is receiving more bipartisan support in the US.
Hello readers. We’re happy to have you with us at Cannadelics.com; a news source here to bring you the best in independent reporting for the growing cannabis and hallucinogen fields. Join us frequently to stay on top of everything, and subscribe to our Cannadelics Weekly Newsletter, for updates straight to your email.Check out some awesome promos for cannabis buds, smoking devices and equipment like vapes, edibles, cannabinoid compounds, magic mushroom products, and a whole bunch more. Let’s all get high together!
The federal administration is all over the board around fed cannabis policy…and millions of patients are worried.
The industry employees over 440,000 workers at all lives and is driven in a large part by mom and pop businesses. Millions use medical marijuana for health issues ranging from chronic pain to sleep. But there are mixed messages from the feds about cannabis, and people are very worried. The federal government’s stance on marijuana has become increasingly complex, as recent developments show conflicting approaches to the drug’s potential benefits and risks. On one hand, there’s a push for research into medical marijuana for veterans, while on the other, a campaign against cannabis use is being launched.
The juxtaposition of initiatives highlights the federal government’s inconsistent approach to marijuana policy. While some departments are exploring the potential benefits of cannabis, others are actively working to discourage its use. This dichotomy is further exemplified by ongoing legislative efforts. For instance, Rep. Brian Mast (R-FL) has reintroduced the Veterans Equal Access Act, which would allow VA doctors to recommend medical marijuana to patients in states where it’s legal. Meanwhile, documents from an ongoing lawsuit suggest that the DEA may have weighted the marijuana rescheduling process to ensure rejection of moving the drug from Schedule 1 to Schedule 3.
Photo by yavdat/Getty Images
The Department of Defense (DOD) has allocated nearly $10 million in funding for research into the therapeutic potential of MDMA for active-duty military members. This initiative, driven by congressional efforts, aims to explore MDMA’s effectiveness in treating conditions such as post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI). Rep. Morgan Luttrell (R-TX) expressed pride in this development, stating that it could be a “game-changer” for service members battling these combat-related injuries.
Additionally, a bipartisan effort in Congress has been pushing for VA research on medical marijuana for PTSD and other conditions affecting veterans. The VA Medicinal Cannabis Research Act, introduced in both the Senate and House, would mandate studies on how cannabis affects the use of addictive medications and impacts various health outcomes for veterans.
In stark contrast to these research initiatives, the Drug Enforcement Administration (DEA) has partnered with an anti-cannabis nonprofit to launch a social media campaign targeting young people. The campaign, set to run ahead of April 20 (4/20), aims to “flood” Instagram with anti-cannabis content. The DEA is offering monetary incentives to students for creating and posting anti-THC videos, with payments ranging from $25 to $50 depending on the type of content produced.
This approach has raised eyebrows, as it seems to contradict the growing acceptance and legalization of marijuana across the United States. Critics argue that such campaigns may be out of touch with current societal trends and scientific understanding of cannabis.
Not everyone has access to marijuana to help them sleep – good news, hemp is available.
it’s estimated 50 to 70 million Canadian and American adults experience sleep disorders or disturbances, and about one-third of adults don’t regularly get the recommended amount. Hemp has emerged as a promising natural remedy for those seeking better sleep. With its calming properties and potential to address various sleep-related issues, hemp-derived products are gaining popularity among individuals looking to improve their rest. Here is how hemp helps you sleep.
Hemp contains several compounds contributing to better sleep quality. Cannabidiol (CBD), a non-psychoactive component of hemp, has shown potential in promoting relaxation and reducing anxiety, which can often interfere with a good night’s rest. Studies suggest that CBD may help individuals fall asleep faster and experience fewer sleep disturbances throughout the night.
When formulated and used properly, preliminary research and user reports suggest that hemp gummies improve subjective sleep quality. Users of quality hemp sleep gummies report feeling more rested, a better quality of sleep and fewer awakenings in the night. However, clinical research has shown that over consumption of THC negatively impacts the quality of sleep, especially with long term use.
Wana Brands has launched a hemp sleeping product nationally, Mike Hennesy, Vice President of Innovation shared the following about how it works. Naturally hemp-derived sleep gummies contain the same cannabinoids like CBD, CBN, and THC as cannabis or marijuana. These ingredients interact with receptors in the body’s endocannabinoid system, which plays a role in regulating mood, stress, and sleep-wake cycles. For example, CBD may promote relaxation and reduce anxiety, CBN can relieve discomfort and reduce awakenings, while THC can shorten the time it takes to fall asleep, especially at low doses. Together, they may help ease the mind and body into a sleep-ready state.
The best sleep products don’t rely on just one cannabinoid like CBN but instead use a combination of cannabinoids, terpenes, and other sleep-supporting ingredients such as melatonin. This is because the reasons for sleeplessness are multifaceted, and include trouble falling asleep, staying asleep, chronic, pain and anxiety. Each ingredient targets different root causes as well as synergizes with the other cannabinoids and terpenes for the best night sleep.
Longer lasting formulations can actually help reduce awakenings in the night. CBN has been shown in recent research to reduce the number of times you wake up in the night. Combined with other cannabinoids they can synergize to reduce discomfort and anxiety helping consumers stay asleep.
If you do wake up in the middle of the night and can’t fall back asleep products including CBD and CBG to reduce middle of the night anxiety and racing thoughts that can keep us awake, and they have only 1mg of THC so you wake up refreshed and not high in the morning.
For most people, hemp-derived cannabinoids are considered safe and non-intoxicating, with a low risk of dependence. When THC is included in small amounts, it can produce mild effects and can help us fall asleep faster. It generally poses a minimal risk when used in moderation, but there is a potential for dependence if overused, just like with any sleep aid. Adverse events are far more prevalent in pharmaceutical and even over the counter sleep aids than with hemp-derived cannabinoids.
The key is responsible use, including starting with a low dose and taking breaks when needed. If you rely on it every night at high doses, your body may adjust, and it can be habitual. But when used in moderation and with a well-balanced formula, cannabis can be a sustainable part of a healthy sleep routine.
Roughly 75% of adults worldwide drink wine, with a significant portion consuming it regularly, and the US wine market sees a substantial number of people drinking wine and refining their taste. In fact, mearly half of adults (44%) drink at least a couple of glasses per week. But this wine issue is becoming more common, Charles Rice, Executive Director of the Wine Education Council shares the following.
Imagine attending a wine tasting, only to discover an unpleasant surprise with one of the bottle. It is bitter and even a little medicinal; it is starting and upsets the balance of the really brings down the whole room and spoils what could have been a lovely evening. This uninvited guest is called ‘smoke taint’ and it a direct result of the increase in wildfires affecting many of the world’s top wine-growing regions. Let’s pour ourselves a glass and explore how this unwanted visitor is crashing the party and what the industry is doing to air out the room.
Smoke taint is like a bad hangover for grapes—it leaves them feeling a bit burned. When wildfires rage nearby, mature and growing grapes absorb volatile compounds, imparting an ashy, smoky flavor to the wine. It’s not just a surface issue: these compounds penetrate deep, forming glycosides that release their smokiness during fermentation. The result? Wines that taste more like a campfire or a doctor’s office than a sophisticated vintage. It’s a “grape” big disappointment!
Rising temperatures and changing weather patterns are fueling longer and more intense fire seasons. This means more frequent and severe wildfires, especially in regions like California, Oregon, and Australia—some of the world’s top wine-producing areas. The impact is twofold: not only do fires directly damage vineyards, but the smoke also compromises grape quality, leaving winemakers feeling crushed. It’s a drain on their passion, and their profits.
Fortunately, researchers are working tirelessly to find ways to put a cork in the problem and coming up with some innovative solutions. Synthetic materials called ‘molecularly imprinted polymers’ can selectively remove smoky compounds from wine without stripping away desirable flavors and aromas. Activated carbon has been shown to be effective but can also remove some of the good stuff. It’s akin to using a broad-spectrum filter that catches both the smoke and some of the wine’s natural charm. Interestingly, producing sparkling wine from smoke-affected grapes is another creative workaround. The carbonation process can mask some of the smoky flavors, turning a potential loss into a bubbly opportunity.
Smoke taint is undoubtedly uninvited guest when it comes to wine in the age of climate change, but the wine industry is not going to complain too much about sour grapes. With innovative solutions and a dash of creativity, winemakers are finding ways to keep the party going. So, the next time you sip a glass of wine, remember the uninvited guest that might have been there, but thanks to science and ingenuity, didn’t ruin the party.